Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.50 |
| ▸ | TERT | O14746 | 4/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | CYCS | P99999 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337728 | 1.00 | GCGR (0.50) | GCGRTERTMGAMGAASI | |
| SCHEMBL2316794 | 1.00 | GCGR (0.50) | GCGRTERTMGAMGAASI | |
| SCHEMBL2313950 | 1.00 | GCGR (0.50) | GCGRTERTMGAMGAASI | |
| SCHEMBL12392093 | 0.92 | GCGR (0.44) | GCGRTERTMGAMGAASI | |
| SCHEMBL20843343 | 0.92 | GCGR (0.44) | GCGRTERTMGAMGAASI | |
| SCHEMBL20843373 | 0.92 | GCGR (0.44) | GCGRTERTMGAMGAASI | |
| SCHEMBL12392085 | 0.92 | GCGR (0.44) | GCGRTERTMGAMGAASI | |
| SCHEMBL12392088 | 0.92 | GCGR (0.47) | GCGRTERTMGAMGAASI | |
| SCHEMBL12392105 | 0.92 | GCGR (0.47) | GCGRMGAMGAASIMGAM2 | |
| SCHEMBL24689639 | 0.91 | GCGR (0.43) | GCGRTERTMGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315510-B2 | Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2016-04-19 | — | — | US | claimed |
| EP-3459955-B1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBERATUNGS II AG (AT) | 2022-11-02 | — | — | EP | disclosed |
| EP-3459955-B1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBERATUNGS II AG (AT) | 2022-11-02 | — | — | EP | disclosed |
| EP-3459955-A1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | biolitec Unternehmensbeteiligungs II AG (AT) | 2019-03-27 | — | — | EP | disclosed |
| EP-3459955-A1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | biolitec Unternehmensbeteiligungs II AG (AT) | 2019-03-27 | — | — | EP | disclosed |
| EP-2350058-B1 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2018-10-24 | — | — | EP | disclosed |
| US-9315510-B2 | Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2016-04-19 | — | — | US | disclosed |
| US-9315510-B2 | Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2016-04-19 | — | — | US | disclosed |
| US-9315510-B2 | Method and application of unsymmetrically meso-substituted porphyrins and chlorins for PDT | BIOLITEC PHARMA MARKETING LTD (MY) | 2016-04-19 | — | — | US | disclosed |
| US-20110206613-A1 | METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2011-08-25 | — | — | US | disclosed |
| US-20110206613-A1 | METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2011-08-25 | — | — | US | disclosed |
| US-20110206613-A1 | METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2011-08-25 | — | — | US | disclosed |
| EP-2350058-A2 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | CeramOptec GmbH (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010033678-A2 | NOVEL METHOD AND APPLICATION OF UNSYMMETRICALLY MESO-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | CERAMOPTEC INDUSTRIES, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206613-A1 | METHOD AND APPLICATION OF UNSYMMETRICALLY meso-SUBSTITUTED PORPHYRINS AND CHLORINS FOR PDT | PTDSS2, PTDSS1, DLST | GCGR 4666/4885TERT 4322/4885MGAM 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.